Multivariable analysis of risk factors for outcome in the MegaCHOEP study (262 young poor-prognosis [aaIPI = 2, 3] patients)
| Risk factor . | EFS . | PFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR [95% CI] without rituximab (n = 0) . | HR [95% CI] with rituximab (n = 262) . | HR [95% CI] without rituximab (n = 0) . | HR [95% CI] with rituximab (n = 262) . | HR [95% CI] without rituximab (n = 0) . | HR [95% CI] with rituximab (n = 262) . | |
| Elevated LDH | - | 1.1 [0.4-3.8] (P = .818) | - | 1.0 [0.3-3.2] (P = .957) | - | 1.2 [0.3-5.3] (P = .778) |
| ECOG performance state >1 | - | 1.6 [1.0-2.5] (P = .034) | - | 1.8 [1.1-2.9] (P = .019) | - | 1.8 [1.0-3.2] (P = .040) |
| Stages III and IV | - | 2.8 [0.7-11.7] (P = .162) | - | 2.4 [0.6-10.0] (P = .245) | - | 3.3 [0.4-24.6] (P = .250) |
| >1 Extralymphatic site | - | 1.2 [0.8-1.8] (P = .357) | - | 1.2 [0.8-1.9] (P = .413) | - | 1.0 [0.6-1.8] (P = .953) |
| Male vs female | - | 1.3 [0.8-2.0] (P = .258) | - | 1.2 [0.7-1.9] (P = .521) | - | 1.0 [0.6-1.7] (P = .900) |
| Risk factor . | EFS . | PFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR [95% CI] without rituximab (n = 0) . | HR [95% CI] with rituximab (n = 262) . | HR [95% CI] without rituximab (n = 0) . | HR [95% CI] with rituximab (n = 262) . | HR [95% CI] without rituximab (n = 0) . | HR [95% CI] with rituximab (n = 262) . | |
| Elevated LDH | - | 1.1 [0.4-3.8] (P = .818) | - | 1.0 [0.3-3.2] (P = .957) | - | 1.2 [0.3-5.3] (P = .778) |
| ECOG performance state >1 | - | 1.6 [1.0-2.5] (P = .034) | - | 1.8 [1.1-2.9] (P = .019) | - | 1.8 [1.0-3.2] (P = .040) |
| Stages III and IV | - | 2.8 [0.7-11.7] (P = .162) | - | 2.4 [0.6-10.0] (P = .245) | - | 3.3 [0.4-24.6] (P = .250) |
| >1 Extralymphatic site | - | 1.2 [0.8-1.8] (P = .357) | - | 1.2 [0.8-1.9] (P = .413) | - | 1.0 [0.6-1.8] (P = .953) |
| Male vs female | - | 1.3 [0.8-2.0] (P = .258) | - | 1.2 [0.7-1.9] (P = .521) | - | 1.0 [0.6-1.7] (P = .900) |